Renaissance Technologies LLC lessened its holdings in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 48.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 154,100 shares of the company’s stock after selling 144,200 shares during the period. Renaissance Technologies LLC’s holdings in Progyny were worth $4,409,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of the business. Farallon Capital Management LLC bought a new stake in shares of Progyny during the first quarter valued at approximately $22,608,000. Wellington Management Group LLP bought a new position in shares of Progyny during the 4th quarter valued at $14,608,000. Norges Bank purchased a new position in shares of Progyny in the 4th quarter worth $14,198,000. Eagle Asset Management Inc. grew its holdings in shares of Progyny by 102.7% in the fourth quarter. Eagle Asset Management Inc. now owns 649,897 shares of the company’s stock worth $24,163,000 after acquiring an additional 329,288 shares during the period. Finally, Redmile Group LLC bought a new position in Progyny in the first quarter valued at about $12,241,000. 94.93% of the stock is currently owned by institutional investors.
Progyny Stock Performance
NASDAQ:PGNY opened at $16.80 on Friday. The stock has a 50 day moving average price of $22.88 and a 200 day moving average price of $27.97. The stock has a market cap of $1.52 billion, a PE ratio of 27.54, a P/E/G ratio of 1.62 and a beta of 1.45. Progyny, Inc. has a one year low of $13.93 and a one year high of $42.08.
Insiders Place Their Bets
In other news, President Michael E. Sturmer sold 9,030 shares of Progyny stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $30.00, for a total value of $270,900.00. Following the completion of the transaction, the president now owns 362,583 shares in the company, valued at approximately $10,877,490. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.30% of the company’s stock.
Analyst Upgrades and Downgrades
PGNY has been the topic of a number of recent analyst reports. Canaccord Genuity Group decreased their target price on shares of Progyny from $24.00 to $18.00 and set a “hold” rating on the stock in a research note on Friday, September 20th. Truist Financial lowered their price objective on Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. JPMorgan Chase & Co. cut their target price on Progyny from $31.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday, September 19th. Leerink Partnrs downgraded Progyny from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Finally, JMP Securities downgraded shares of Progyny from an “outperform” rating to a “market perform” rating in a report on Thursday, September 19th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $27.73.
View Our Latest Research Report on PGNY
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Articles
- Five stocks we like better than Progyny
- 3 Monster Growth Stocks to Buy Now
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 9/23 – 9/27
- Insider Trades May Not Tell You What You Think
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.